WO2007064311A1 - Micronized mirtazapine - Google Patents

Micronized mirtazapine Download PDF

Info

Publication number
WO2007064311A1
WO2007064311A1 PCT/US2001/021595 US0121595W WO2007064311A1 WO 2007064311 A1 WO2007064311 A1 WO 2007064311A1 US 0121595 W US0121595 W US 0121595W WO 2007064311 A1 WO2007064311 A1 WO 2007064311A1
Authority
WO
WIPO (PCT)
Prior art keywords
mirtazapine
micronized
mean particle
microns
particle diameter
Prior art date
Application number
PCT/US2001/021595
Other languages
French (fr)
Inventor
Claude Singer
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceutical Industries Ltd.
Priority to PCT/US2001/021595 priority Critical patent/WO2007064311A1/en
Publication of WO2007064311A1 publication Critical patent/WO2007064311A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Definitions

  • This invention relates to micronized mirtazapine and to the preparation thereof.
  • Mirtazapine has a tetracyclic chemical structure unrelated to
  • antidepressants such as selective serotonin reuptake inhibitors, tricyclics or
  • the velocity of dissolution of a drug often effects the drug's bioavailability.
  • PSD of mirtazapine and, in particular, the mean particle diameter are important parameters to
  • the mean particle size enhances the reporducability of the rat of dissolution and the reproducibility of the dissolution. It is desirable to have mirtazapine in which the mean particle size imparts an improved and stable dissolution profile.
  • the present invention relates to mirtazapine and mirtazapine formulations containing mirtazapine having relatively small particles, and corresponding relatively large surface area.
  • the invention relates to mirtazapine having a mean particle
  • mean particle diameter of less than 200 micrometer preferably mean particle diameter is less than 100 microns, more preferably the mean particle diameter is less than 20 microns, most preferably the mean particle size is between about 10 and 20 microns.
  • Micronized mirtazapine is used
  • mirtazapine having a mean particle diameter of about 200 to about 10
  • the present invention relates to a
  • Mirtazapine prepared by methods known the art, is separated by sieves to produce mirtazapine having a mean particle diameter of about
  • the mirtazapine has a mean particle diameter of about
  • mirtazapine having a mean particle size of less than 200 microns. Preferable the mirtazapine
  • isolated has a mean particle diameter of less than 100 microns, more preferably less than 20 microns and most preferably about 10 microns.
  • the micronized mirtazapine is made from dry mirtazapine.
  • the present invention relates to a pharmaceutical composition comprising micronized mirtazapine.
  • micronized mirtazapine has a superior dissolution profile compared to mirtazapine prior to micronization, including enhanced reproducibility of dissolution.
  • micronized mirtazapine provides a form of mirtazapine in which the determination of an optimal dose is easier to determine and reproduce when compared to non- micronized mirtazapine.
  • Figure 1 is a graph of the dissolution data of mirtazapine before and after
  • Figure 2 is a graph of the percent of dissolved mirtazapine before and after micronization.
  • Figure 3 is a graph of showing the dissolution time and standard deviations of the dissolution results before and after micronization.
  • the present invention relates to mirtazapine formulations containing mirtazapine
  • the invention relates to mirtazapine and formulations containing mirtazapine having a mean particle diameter of less than 200 micrometer, preferably the mean
  • mirtazapine has a mean particle diameter of between about 200 microns and 10 microns. In another embodiment of the present invention, mirtazapine has a mean length of about 4.2 microns, more preferably a mean length of 4.0 microns.
  • the present micronized mirtazapine has the unexpected results of possessing a more stable and reproducible dissolution profile. When compared to mirtazapine make by conventional methods, the present micronized mirtazapine unexpectedly demonstrated a more reproducible dissolution curve and a smaller standard of deviations. This is valuable
  • the present invention relates to a
  • Mirtazapine prepared by methods known in
  • mirtazapine wherein 50% has a mean particle diameter of below about 250 microns and about 80% has is below about 500 microns.
  • the sieved mirtazapine is then micronized by methods known in the art, e.g., in a micronizer, to yield mirtazapine wherein 100% of the mirtazapine has a mean particle size of less than about 45 microns, preferably 99% of the mirtazapine has a mean particle size of less than about 45
  • microns more preferably, 93% of the mirtazapine has a mean particle size of less than about
  • the mirtazapine isolated has a mean particle diameter of less
  • Micronized particles of mirtazapine can be obtained by the use of conventional
  • micronizing techniques after sieving to provide mirtazapine wherein about 50% has a particle size less than 250 microns and about 80% has a particle sized below about 500 microns.
  • Mirtazapine may be micronized to the desired particle size range by conventional techniques, for example, using a ball mill, ultrasonic means, or using fluid energy attrition mills.
  • mirtazapine is made from dry mirtazapine.
  • the present invention relates to a pharmaceutical
  • composition comprising micronized mirtazapine.
  • mirtazapine produced by the process of the present invention.
  • compositions that are particularly useful for the treatment of depression.
  • Such compositions comprise a therapeutically effective
  • Pure dry Mirtazapine was micronized in a micronizer.
  • the isolated product was micronized mirtazapine of a particle size of about 10 to 20 micrometer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to mirtazapine having relatively small particles, and corresponding relatively large surface area. In one embodiment, the invention relates to mirtazapine and formulations containing mirtazapine having a mean particle diameter of less than 200 micrometer.

Description

MICRONIZED MIRTAZAPINE
CROSS-REFERENCE TO RELATED APPLICATION
The present application claims benefit of U.S provisional application Ser. No. 60/216,564, filed July 7, 2000, which is incorporated by reference.
FIELD OF THE INVENTION
This invention relates to micronized mirtazapine and to the preparation thereof.
BACKGROUND OF THE INVENTION
Mirtazapine, 1 ,2,3,4, 10, 14b-hexahydro-2-methyl-pyrazino [2, 1 -a]pyrido[2,3-c] [2]
benzazepine, having the formula I:
Figure imgf000002_0001
is approved, under the trademark Remeron®, by the U.S. Food and Drug Administration, for the treatment of depression. Mirtazapine has a tetracyclic chemical structure unrelated to
other classes of antidepressants such as selective serotonin reuptake inhibitors, tricyclics or
monoamine oxidase inhibitors.
U.S. Patent No. 4,062,848, the contents of which is incorporated by reference, discloses a process for making mirtazapine. Mirtazapine is essentially insoluble in water. The Particle Size Distribution (PSD) of mirtazapine crystals may be used to determine the available surface area for the drug
dissolution thus effecting the solubility. Often, it is observed that the available surface area
for drug dissolution correlates to the rate of dissolution and solubility where a greater surface
area enhances the solubility fa drug and enhances the rate of dissolution of a drug. Further,
the velocity of dissolution of a drug often effects the drug's bioavailability. Thus the PSD of mirtazapine and, in particular, the mean particle diameter are important parameters to
characterize and predict the bioavailability of the drug. It is desireable to have mirtazapine
with a particle size in which the mean particle size enhances the reporducability of the rat of dissolution and the reproducibility of the dissolution. It is desirable to have mirtazapine in which the mean particle size imparts an improved and stable dissolution profile.
SUMMARY OF THE INVENTION
The present invention relates to mirtazapine and mirtazapine formulations containing mirtazapine having relatively small particles, and corresponding relatively large surface area.
In one embodiment, the invention relates to mirtazapine having a mean particle
diameter of less than 200 micrometer, preferably mean particle diameter is less than 100 microns, more preferably the mean particle diameter is less than 20 microns, most preferably the mean particle size is between about 10 and 20 microns. Micronized mirtazapine is used
herein as referring to mirtazapine having a mean particle diameter of about 200 to about 10
microns.
According to another embodiment of the invention, the present invention relates to a
process for preparing micronized mirtazapine. Mirtazapine, prepared by methods known the art, is separated by sieves to produce mirtazapine having a mean particle diameter of about
350 to about 250 microns. Preferably the mirtazapine has a mean particle diameter of about
300 to 250 microns. The sieved mirtazapine is then micronized in a micronized to yield
mirtazapine having a mean particle size of less than 200 microns. Preferable the mirtazapine
isolated has a mean particle diameter of less than 100 microns, more preferably less than 20 microns and most preferably about 10 microns.
According to another embodiment of the present invention, the micronized mirtazapine is made from dry mirtazapine.
According to another aspect, the present invention relates to a pharmaceutical composition comprising micronized mirtazapine.
It has been surprisingly and unexpectedly found that micronized mirtazapine has a superior dissolution profile compared to mirtazapine prior to micronization, including enhanced reproducibility of dissolution.
Surprisingly, micronized mirtazapine provides a form of mirtazapine in which the determination of an optimal dose is easier to determine and reproduce when compared to non- micronized mirtazapine.
DESCRIPTION OF THE FIGURES
Figure 1 is a graph of the dissolution data of mirtazapine before and after
micronization.
Figure 2 is a graph of the percent of dissolved mirtazapine before and after micronization. Figure 3 is a graph of showing the dissolution time and standard deviations of the dissolution results before and after micronization.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to mirtazapine formulations containing mirtazapine
having relatively small particles, and corresponding relatively large surface area.
In one embodiment, the invention relates to mirtazapine and formulations containing mirtazapine having a mean particle diameter of less than 200 micrometer, preferably the mean
particle diameter is less than 100 microns, more preferably the mean particle diameter is less than 20 microns, most preferably the mean particle size is between about 10 microns. In another embodiment of the present invention, mirtazapine has a mean particle diameter of between about 200 microns and 10 microns. In another embodiment of the present invention, mirtazapine has a mean length of about 4.2 microns, more preferably a mean length of 4.0 microns.
The present micronized mirtazapine has the unexpected results of possessing a more stable and reproducible dissolution profile. When compared to mirtazapine make by conventional methods, the present micronized mirtazapine unexpectedly demonstrated a more reproducible dissolution curve and a smaller standard of deviations. This is valuable
improvement provides for more accurate dosing of mirtazapine.
According to another embodiment of the invention, the present invention relates to a
process for preparing micronized mirtazapine. Mirtazapine prepared by methods known in
the art is separated by sieves to produce mirtazapine wherein 50% has a mean particle diameter of below about 250 microns and about 80% has is below about 500 microns. The sieved mirtazapine is then micronized by methods known in the art, e.g., in a micronizer, to yield mirtazapine wherein 100% of the mirtazapine has a mean particle size of less than about 45 microns, preferably 99% of the mirtazapine has a mean particle size of less than about 45
microns, more preferably, 93% of the mirtazapine has a mean particle size of less than about
7.5 microns, more preferably the mirtazapine isolated has a mean particle diameter of less
than 10 micron.
Micronized particles of mirtazapine can be obtained by the use of conventional
micronizing techniques after sieving to provide mirtazapine wherein about 50% has a particle size less than 250 microns and about 80% has a particle sized below about 500 microns.
Mirtazapine may be micronized to the desired particle size range by conventional techniques, for example, using a ball mill, ultrasonic means, or using fluid energy attrition mills.
According to another embodiment of the present invention, the micronized
mirtazapine is made from dry mirtazapine.
According to another aspect, the present invention relates to a pharmaceutical
composition comprising micronized mirtazapine.
In accordance with the present invention, mirtazapine produced by the process of the
present invention may be prepared as pharmaceutical compositions that are particularly useful for the treatment of depression. Such compositions comprise a therapeutically effective
amount of mirtazapine with pharmaceutically acceptable carriers and/or excipients known to
one of skill in the art. EXAMPLES
' The present invention will now be further explained in the following example.
However, the present invention should not be construed as limited thereby. One of ordinary
skill in the art will understand how to vary the exemplified preparations to obtain the desired
results.
It should be understood that some modification, alteration and substitution is
anticipated and expected from those skilled in the art without departing from the teachings of the invention. Accordingly, it is appropriate that the following claims be construed broadly and in a manner consistent with the scope and spirit of the invention.
Example 1
Pure dry Mirtazapine was micronized in a micronizer. The isolated product was micronized mirtazapine of a particle size of about 10 to 20 micrometer.

Claims

1. Mirtazapine having a mean particle diameter of less than 200 micrometer.
2. Mirtazapine of claim 1 wherein the mean particle diameter of less than 100
micrometer.
3. Mirtazapine of claim 2 wherein the mean particle diameter of less than about 20 micrometer.
4. Mirtazapine of claim 3 wherein the mean particle diameter is about 10 micrometer.
5. Mirtazapine of claim 1 wherein the mean particle size of less than 100 micrometers and greater than 10 micrometers.
6. A process for preparing micronized mirtazapine, which comprises micronizing
mirtazapine.
7. The process according to claim 6 wherein the mirtazapine that is to be
micronized is purified mirtazapine
8. The process according to claim 6 in which the mirtazapine that is to be
micronized is dry mirtazapine.
9. The process of claim 6 wherein the mirtazapine that is to be micronized has a mean particle diameter of about 300 microns.
10. The process of claim 6 wherein the mirtazapine that is to be micronized has a
mean particle diameter of about 250 microns.
11. Mirtazapine with a mean diameter of about 10 microns.
12. A pharmaceutical composition comprising a therapeutically effective amount micronized mirtazapine as claimed in any of claims 1 and 11.
PCT/US2001/021595 2001-07-10 2001-07-10 Micronized mirtazapine WO2007064311A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021595 WO2007064311A1 (en) 2001-07-10 2001-07-10 Micronized mirtazapine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021595 WO2007064311A1 (en) 2001-07-10 2001-07-10 Micronized mirtazapine

Publications (1)

Publication Number Publication Date
WO2007064311A1 true WO2007064311A1 (en) 2007-06-07

Family

ID=38092533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021595 WO2007064311A1 (en) 2001-07-10 2001-07-10 Micronized mirtazapine

Country Status (1)

Country Link
WO (1) WO2007064311A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10603272B2 (en) 2015-02-27 2020-03-31 Kindred Biosciences, Inc. Stimulation of appetite and treatment of anorexia in dogs and cats

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202129A (en) * 1989-08-04 1993-04-13 Tanabe Seiyaku Co., Ltd. Process for micronizing slightly-soluble drug
US6228346B1 (en) * 1996-04-25 2001-05-08 Pari Gmbh Spezialisten Fur Effektive Inhalation Propellant mixtures and aerosols for micronizing medicaments with compressed gas
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202129A (en) * 1989-08-04 1993-04-13 Tanabe Seiyaku Co., Ltd. Process for micronizing slightly-soluble drug
US6228346B1 (en) * 1996-04-25 2001-05-08 Pari Gmbh Spezialisten Fur Effektive Inhalation Propellant mixtures and aerosols for micronizing medicaments with compressed gas
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10603272B2 (en) 2015-02-27 2020-03-31 Kindred Biosciences, Inc. Stimulation of appetite and treatment of anorexia in dogs and cats

Similar Documents

Publication Publication Date Title
Vimalson Techniques to enhance solubility of hydrophobic drugs: an overview
EP0411629B1 (en) A process for micronizing slightly-soluble drug
JP2003026607A (en) Pharmaceutical composition comprising medicine and concentration-enhancing polymer
CN103338749B (en) Form of administration of enkephalinase inhibitor
NO164817B (en) PROCEDURE FOR THE PREPARATION OF TWO-PHASE, NIFEDIP-CONTAINED, PHARMACEUTICAL PREPARATIONS.
TWI380829B (en) Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion
US10596263B2 (en) Pazopanib formulation
JP2008534520A (en) Methods for developing drugs as potent and selective inhibitors of phosphodiesterase type 1 to 5 isoforms (PDE1, PDE2, PDE3, PDE4, PDE5) based on dioclein, floranol or analogs and research on cardiovascular diseases And their pharmaceutical compositions and related products for treatment
JP2009515830A (en) Micronized azodicarbonamide, its preparation and its use
US20020072602A1 (en) Micronized mirtazapine
EP1465628A2 (en) Fine particle size pioglitazone
WO2007064311A1 (en) Micronized mirtazapine
HU229075B1 (en) Method for the production and use of spherical telithromycin clusters in the preparation of pharmaceutical forms
BG61340B1 (en) Benzene-dimethanol derivative, suitable micronizating
CA1317595C (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as an active substance
Sheth Formulation and evaluation of solid dispersion of olanzepine
US20020077485A1 (en) Micronized leflunomide
US20020120147A1 (en) Micronized torsemide
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof
FR2757543A1 (en) PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED
Nandgude et al. Development of self-micro emulsifying drug delivery system based solid dosage form containing simvastatin
PL66157B1 (en)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application